2014
Intra-Subtype Variation in Enteroadhesion Accounts for Differences in Epithelial Barrier Disruption and Is Associated with Metronidazole Resistance in Blastocystis Subtype-7
Wu Z, Mirza H, Tan KS. Intra-Subtype Variation in Enteroadhesion Accounts for Differences in Epithelial Barrier Disruption and Is Associated with Metronidazole Resistance in Blastocystis Subtype-7. PLOS Neglected Tropical Diseases 2014, 8: e2885. PMID: 24851944, PMCID: PMC4031124, DOI: 10.1371/journal.pntd.0002885.Peer-Reviewed Original ResearchConceptsEpithelial barrier disruptionBarrier disruptionDrug resistanceBlastocystis subtype 7Intra-subtype variationOccludin tight junction proteinsEpithelial barrier dysfunctionDiverse clinical outcomesParasite virulence factorsTight junction proteinsCaco-2 cellsClinical outcomesBarrier dysfunctionIntestinal disordersMetronidazole resistanceBlastocystis infectionSubtype 7Metronidazole susceptibilityHost responseIntestinal epitheliumEnteric pathogensNitrosative stressResistant strainsJunction proteinsLuminal stages
2010
A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent Variations in Drug Susceptibilities
Mirza H, Teo JD, Upcroft J, Tan KS. A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent Variations in Drug Susceptibilities. Antimicrobial Agents And Chemotherapy 2010, 55: 637-648. PMID: 21098237, PMCID: PMC3028762, DOI: 10.1128/aac.00900-10.Peer-Reviewed Original ResearchConceptsTreatment failureBlastocystis infectionBlastocystis sppNew treatment optionsDrug-resistant isolatesStandard therapyTreatment regimensTreatment optionsMetronidazole resistanceControversial pathogenesisSubtype 4Drug susceptibilityImportant subtypeDrug sensitivitySubtypesStandard antimicrobialsInfectionZoonotic subtypesViability assaysPresent studyParasitesFirst studyCotrimoxazoleRegimensFailure
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply